ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1966

Favorable Effects of TNF Inhibitors on Intima Media Thickness and Arterial Stiffness in Rheumatoid Arthritis: A Systematic Review and Meta-analysis

Eva van Geel1, Bafrin Abdulmajid1, Annelies Blanken2 and Michael Nurmohamed3, 1Reade Rheumatology Center, Amsterdam, Netherlands, 2Amsterdam University Medical Centers, Amsterdam, Netherlands, 3Amsterdam University Medical Center, Kortenhoef, Netherlands

Meeting: ACR Convergence 2022

Keywords: Anti-TNF Drugs, Cardiovascular, meta-analysis, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster IV

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Controlling inflammation with tumour necrosis factor (TNF) inhibitors in rheumatoid arthritis (RA) patients is hypothesized to reduce their cardiovascular risk. Arterial wall thickness (carotid intima media thickness (IMT)) and arterial stiffness (pulse wave velocity (PWV) and augmentation index (AIx)) are well established markers for subclinical cardiovascular disease and can be used as surrogate endpoints. A systematic review and meta-analysis on the effects of TNF inhibitors on arterial stiffness and carotid IMT in RA was performed.

Methods: MEDLINE, EMBASE, clinicaltrials.gov and WHO Clinical Trials Registry were searched for studies evaluating the effects of TNF inhibitors on PWV, AIx and IMT in RA.

Only controlled trials and prospective cohort studies were included. Principal study measures were baseline, follow-up and mean difference of the primary outcome measures IMT, PWV and AIx after TNF inhibiting treatment. A meta-analysis was performed to assess changes of these measures after therapy during different follow-up periods.

Results: 30 studies were identified from 1436 records, of which 23 were included in the meta-analysis. For IMT, there was a slight increase in the first months of follow-up, however the long-term follow-up revealed no progression (mean difference (MD) overall timepoints 0.01 mm (95%CI -0.04 – 0.02), p=0.61). PWV and AIx showed a decrease after treatment (PWV: MD -0.51 m/s (95%CI -0.96 – -0.06), p=0.03; AIx: MD -0.57 % (95%CI -2.11 – 0.96), p=0.46). Heterogeneity was high in the overall analyses and subgroups with long follow-up periods (≥12 months).

Conclusion: This meta-analysis showed mixed results of the effects of TNF inhibitors on the surrogate markers. The results suggest that TNF inhibiting therapy in RA patients does not deteriorate intima media thickness and decreases PWV and AIx. This indicates favorable effects of TNF inhibitors on the cardiovascular disease risk. Whether this ultimately leads to less clinically overt cardiovascular events in comparison to other antirheumatic therapies needs further investigation.

Supporting image 1

Table 1. Results of meta-analysis
Results of meta-analyses for IMT, PWV and Aix for different time intervals, given in mean difference over time with 95% confidence interval, p-value and I2. *: P-value is significant. The mean difference for IMT is given as millimeter, for PWV as meter/second and for AIx as percentage. I2 is given as percentage.
Summary estimate: the model includes all timepoints, except when in one study the same patients were measured multiple times, the longest follow-up time was used.
IMT: inter media thickness; PWV: pulse wave velocity; AIx: augmentation index, m: months, 95%CI: 95% confidence interval.

Supporting image 2

Figure 1. Forest Plot for PWV comparing different time intervals
Data are presented as mean difference over time in meter/second with 95% confidence interval.
Summary estimate T: the model includes all timepoints, except when in one study the same patients were measured multiple times, the longest follow-up time was used.
PWV: pulse wave velocity; MD: mean difference; m/s: meter/second; 95%CI, 95% confidence interval.


Disclosures: E. van Geel, None; B. Abdulmajid, None; A. Blanken, None; M. Nurmohamed, AbbVie/Abbott.

To cite this abstract in AMA style:

van Geel E, Abdulmajid B, Blanken A, Nurmohamed M. Favorable Effects of TNF Inhibitors on Intima Media Thickness and Arterial Stiffness in Rheumatoid Arthritis: A Systematic Review and Meta-analysis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/favorable-effects-of-tnf-inhibitors-on-intima-media-thickness-and-arterial-stiffness-in-rheumatoid-arthritis-a-systematic-review-and-meta-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/favorable-effects-of-tnf-inhibitors-on-intima-media-thickness-and-arterial-stiffness-in-rheumatoid-arthritis-a-systematic-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology